Abstract 1389
Background
Anti-VEGF & anti-DLL4 have both demonstrated single agent activity in ovarian cancer. Navicixizumab is an anti-DLL4/VEGF IgG2 bispecific monoclonal antibody that had a response rate of 25% (3/12) in heavily pretreated ovarian cancer pts who were treated in an earlier single agent phase Ia trial.
Methods
This is an ongoing Phase 1b study of paclitaxel & navicixizumab in platinum resistant ovarian cancer pts who have failed > 2 prior therapies &/or bevacizumab. Paclitaxel 80 mg/m2 is given on Days 1, 8 and 15 & navicixizumab is given on Days 1 & 15 of every 28 day cycle. This study was designed as a dose escalation trial testing navicixizumab doses of 3 or 4 mg/kg followed by an expansion cohort to enroll a total of 30 patients. The expansion cohort was undertaken with 3 mg/kg of navicixizumab as higher doses did not show increased activity, but did result in more pronounced chronic toxicity in the Phase 1a study. A standardized treatment algorithm for hypertension is being employed.
Results
Eighteen pts were treated; 5 are still ongoing. The median number of prior therapies was 4 (range 2-8), all 18 pts had received prior paclitaxel & 13 had received bevacizumab. Eight pts (44%) had a PR, 6 (33%) had SD, 2 (11%) had PD & 2 (11%) were NE. The clinical benefit rate was 78%. Ten of 14 (71%) pts with an elevated CA-125 had a GCIG-defined response. The related AEs (all grades) that occurred in > 15% of the pts were: hypertension (67%), fatigue (44%), diarrhea (44%), headache (22%), neutropenia (17%), GERD (17%) & decrease appetite (17%). Other related AEs of significance were an infusion reaction (6%), Gr2 pulmonary hypertension (6%), Gr 4 thrombocytopenia (6%) & Gr4 GI perforation (6%). Anti-drug antibody occurred in 3 of 16 pts who have been evaluated; drug exposure was impacted in 1 pt.
Conclusions
The efficacy data in these heavily pre-treated platinum resistant ovarian cancer pts are encouraging & enrollment is ongoing. The safety profile appears to be manageable with hypertension being the most common adverse event related to navicixizumab.
Clinical trial identification
NCT03030287 January 25, 2017.
Legal entity responsible for the study
OncoMed Pharmaceuticals.
Funding
OncoMed Pharmaceuticals.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract